About Sophiris Bio (NASDAQ:SPHS)
Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 and other products for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate. The company was formerly known as Protox Therapeutics Inc. and changed its name to Sophiris Bio, Inc. in April 2012. Sophiris Bio, Inc. was founded in 2002 and is based in La Jolla, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SPHS
CUSIPN/A
Phone858-777-1760
Debt
Debt-to-Equity Ratio0.84%
Current Ratio9.94%
Quick Ratio9.94%
Price-To-Earnings
Trailing P/E Ratio-5.41
Forward P/E Ratio-4.09
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.25 per share
Price / Book8.68
Profitability
EPS (Most Recent Fiscal Year)($0.40)
Net Income$-8,620,000.00
Net MarginsN/A
Return on Equity-108.75%
Return on Assets-44.37%
Miscellaneous
Employees6
Outstanding Shares30,110,000
Sophiris Bio (NASDAQ:SPHS) Frequently Asked Questions
What is Sophiris Bio's stock symbol?
Sophiris Bio trades on the NASDAQ under the ticker symbol "SPHS."
How were Sophiris Bio's earnings last quarter?
Sophiris Bio (NASDAQ:SPHS) posted its quarterly earnings data on Thursday, March, 29th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by $0.02. View Sophiris Bio's Earnings History.
What price target have analysts set for SPHS?
3 Wall Street analysts have issued 1-year price objectives for Sophiris Bio's stock. Their forecasts range from $5.00 to $6.00. On average, they anticipate Sophiris Bio's share price to reach $5.6667 in the next twelve months. View Analyst Ratings for Sophiris Bio.
Who are some of Sophiris Bio's key competitors?
Some companies that are related to Sophiris Bio include BioDelivery Sciences International (BDSI), Checkpoint Therapeutics (CKPT), Adamis Pharmaceuticals (ADMP), Galectin Therapeutics (GALT), Axovant Sciences (AXON), AcelRx Pharmaceuticals (ACRX), Otonomy (OTIC), Bellerophon Therapeutics (BLPH), ContraFect (CFRX), Merrimack Pharmaceuticals (MACK), OncoMed Pharmaceuticals (OMED), Infinity Pharmaceuticals (INFI), CytoDyn (CYDY), Trevena (TRVN), ProQR Therapeutics (PRQR), Leap Therapeutics (LPTX), Cumberland Pharmaceuticals (CPIX) and Conatus Pharmaceuticals (CNAT).
Who are Sophiris Bio's key executives?
Sophiris Bio's management team includes the folowing people:
- Mr. Randall E. Woods, Pres, CEO & Director (Age 66)
- Mr. Peter T. Slover CPA, Chief Financial Officer (Age 43)
- Dr. Allison J. Hulme Ph.D., COO, Head of R&D and Director (Age 55)
- Dr. Samuel R. Denmeade M.D., Chief Scientific Officer and Member of the Scientific Advisory Board
- Dr. James Joseph Beesley BSc, DC, Sr. Director of Investor Relations (Age 46)
Has Sophiris Bio been receiving favorable news coverage?
News coverage about SPHS stock has been trending somewhat positive recently, Accern reports. The research group rates the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Sophiris Bio earned a coverage optimism score of 0.09 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 47.00 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
How do I buy shares of Sophiris Bio?
Shares of SPHS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sophiris Bio's stock price today?
One share of SPHS stock can currently be purchased for approximately $2.17.
How big of a company is Sophiris Bio?
Sophiris Bio has a market capitalization of $65.64 million. The biopharmaceutical company earns $-8,620,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis. Sophiris Bio employs 6 workers across the globe.
How can I contact Sophiris Bio?
Sophiris Bio's mailing address is 1258 PROSPECT STREET, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-777-1760 or via email at [email protected]
MarketBeat Community Rating for Sophiris Bio (SPHS)
MarketBeat's community ratings are surveys of what our community members think about Sophiris Bio and other stocks. Vote "Outperform" if you believe SPHS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPHS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Sophiris Bio (NASDAQ:SPHS) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for Sophiris Bio in the last 12 months. Their average twelve-month price target is $5.6667, suggesting that the stock has a possible upside of 161.14%. The high price target for SPHS is $6.00 and the low price target for SPHS is $5.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $5.6667 | $6.00 | $6.25 | $6.60 |
| Price Target Upside: | 161.14% upside | 200.00% upside | 175.33% upside | 207.55% upside |
Sophiris Bio (NASDAQ:SPHS) Consensus Price Target History
Sophiris Bio (NASDAQ:SPHS) Analyst Ratings History
Show:
(Data available from 4/20/2016 forward)
Sophiris Bio (NASDAQ:SPHS) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Sophiris Bio (NASDAQ SPHS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 3.90%
Institutional Ownership Percentage: 6.37%
Sophiris Bio (NASDAQ SPHS) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/15/2014 | Boxer Capital, Llc | Major Shareholder | Sell | 881,479 | $0.61 | $537,702.19 | |  |
| 11/14/2014 | Randall E Woods | Insider | Buy | 3,000 | $2.43 | $7,290.00 | | |
| 9/19/2014 | Gerald T Proehl | Director | Buy | 10,000 | $3.16 | $31,600.00 | | |
| 7/10/2014 | Randall E Woods | Insider | Buy | 1,000 | $2.65 | $2,650.00 | | |
| 7/9/2014 | Randall E Woods | Insider | Buy | 1,000 | $2.66 | $2,660.00 | | |
| 6/6/2014 | James L Heppell | Director | Sell | 19,231 | $2.59 | $49,808.29 | | |
| 8/22/2013 | Randall E Woods | CEO | Buy | 2,500 | $4.50 | $11,250.00 | | |
| 8/20/2013 | Peter T Slover | CFO | Buy | 4,680 | $4.25 | $19,890.00 | | |
| 8/19/2013 | Randall E Woods | CEO | Buy | 10,000 | $4.29 | $42,900.00 | | |
| 8/16/2013 | Boxer Capital, Llc | Major Shareholder | Buy | 1,600,000 | $5.00 | $8,000,000.00 | | |
(Data available from 1/1/2013 forward)
Sophiris Bio (NASDAQ SPHS) News Headlines
| Source: |
|
Sophiris Bio (NASDAQ:SPHS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Sophiris Bio (NASDAQ:SPHS) Income Statement, Balance Sheet and Cash Flow Statement
Sophiris Bio (NASDAQ SPHS) Stock Chart for Friday, April, 20, 2018
Loading chart…
